|

RC48 Clinical Trials

3 actively recruiting trials

▼ -1 trial since June 2026

Also known as: Disitamab Vedotin

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Tianjin Medical University Second Hospital1
  • The First Affiliated Hospital with Nanjing Medical University1
  • Fudan University1

Indications

  • Cancer3
  • CDK12 Gene Mutation1
  • GC/GEJC1
  • Mammary or Extramammary Paget's Disease1
  • Prostate Cancer1

Other3 trials

A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
Phase 2
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
Phase 2
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.